Centuri (CTRI) Stock Price, News & Analysis

Company Overview

Centuri (NYSE:CTRI) is a global contract development and manufacturing organization (CDMO) specializing in advanced aseptic processing for both conventional and radiopharmaceutical products. The company offers comprehensive end-to-end solutions that span from early-stage development through commercial supply. Its core capabilities include sterile fill-finish, lyophilization, labeling, secondary packaging, and cold-chain distribution designed to meet the exacting requirements of small molecule, biologic, and solid dose drug products.

With an emphasis on radiolabeled compounds, Centuri provides specialized support for oncology and theranostic pipelines, offering bespoke radiochemistry, quality control testing, and regulatory dossier preparation. Beyond radiopharmaceuticals, the firm serves a broad range of therapeutic areas, delivering process development, analytical method qualification, and stability studies. Centuri’s integrated quality systems, backed by ISO accreditation and adherence to current Good Manufacturing Practices (cGMP), ensure that products are consistently manufactured and tested to the highest standards.

Founded in the mid-1990s, Centuri has evolved from a regional fill-finish provider into a multi-site organization with strategically located facilities in the United States, Europe, and Asia Pacific. Its global footprint enables seamless supply chain management and geographic diversification, supporting clients from biotech start-ups to multinational pharmaceutical companies. The company’s investments in single-use technologies, modular cleanrooms, and digital batch record systems underscore its commitment to operational excellence and scalable capacity.

Centuri’s leadership team combines deep industry experience in pharmaceutical manufacturing, regulatory affairs and business development. This seasoned executive bench drives strategic expansion while maintaining a strong focus on compliance, quality assurance and customer collaboration. Under their guidance, the company continues to bolster its service offerings, pursue targeted partnerships and respond to the evolving demands of the global life sciences sector.

Key Stats

• Today's Range: $20.64 to $21.24
• 50-Day Range: $18.36 to $23.06
• 52-Week Range: $14.46 to $24.60
• Volume: 614,934 shs
• Average Volume: 474,992 shs
• Market Capitalization: $1.85 billion
• P/E Ratio: 62.88
• Dividend Yield: N/A
• Price Target: $19.60
• Consensus Rating: Hold

Centuri Stock Analysis - MarketRank™

Centuri scored higher than 13% of companies evaluated by MarketBeat, and ranked 94th out of 96 stocks in the utilities sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.0 / 5
• Analyst Rating: Hold

Consensus Rating

Centuri has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 2 buy ratings, 1 hold rating, and 2 sell ratings.

Amount of Analyst Coverage

Centuri has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 108.00%

Earnings Growth

Earnings for Centuri are expected to grow by 108.00% in the coming year, from $0.25 to $0.52 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Centuri is 62.88, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.50.

Price to Earnings Ratio vs. Sector

The P/E ratio of Centuri is 62.88, which means that it is trading at a more expensive P/E ratio than the Utilities sector average P/E ratio of about 19.94.

Price to Earnings Growth Ratio

Centuri has a PEG Ratio of 1.13. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Centuri has a P/B Ratio of 3.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.57% of the float of Centuri has been sold short.

Short Interest Ratio / Days to Cover

Centuri has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Centuri has recently increased by 28.08%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Centuri does not currently pay a dividend.

Dividend Growth

Centuri does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.57% of the float of Centuri has been sold short.

Short Interest Ratio / Days to Cover

Centuri has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Centuri has recently increased by 28.08%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.43

News Sentiment

Centuri has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Utilities companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Centuri this week, compared to 3 articles on an average week.

MarketBeat Follows

1 people have added Centuri to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Centuri insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.15% of the stock of Centuri is held by insiders.

CTRI Stock Analysis - Frequently Asked Questions

How have CTRI shares performed this year?

Centuri's stock was trading at $19.31 at the start of the year. Since then, CTRI stock has increased by 8.1% and is now trading at $20.87.

How were Centuri's earnings last quarter?

Centuri Holdings, Inc. (NYSE:CTRI) announced its quarterly earnings data on Monday, May, 12th. The company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.02. The company's quarterly revenue was up 4.2% on a year-over-year basis.
Read the conference call transcript.

When did Centuri IPO?

Centuri (CTRI) raised $260 million in an initial public offering (IPO) on Thursday, April 18th 2024. The company issued 12,400,000 shares at $21.00 per share.

How do I buy shares of Centuri?

Shares of CTRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Centuri own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Centuri investors own include Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Visa (V).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/17/2025
• Next Earnings (Estimated): 8/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Utilities
• Industry: UTIL - ELEC PWR
• Sub-Industry: Utilities
• Current Symbol: NYSE:CTRI
• Previous Symbol: NYSE:CTRI
• CIK: 1981599
• Web: centuri.com
• Phone: 623-582-1235
• Fax: N/A
• Employees: 8,600
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Centuri: $19.60
• High Price Target: $25.00
• Low Price Target: $15.00
• Potential Upside/Downside: -6.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.02
• Trailing P/E Ratio: 1,050.78
• Forward P/E Ratio: 84.02
• P/E Growth: 1.12
• Net Income: -$6.72 million
• Net Margins: 0.02%
• Pretax Margin: 0.44%
• Return on Equity: 5.16%
• Return on Assets: 1.32%

Debt

• Debt-to-Equity Ratio: 1.56
• Current Ratio: 1.57
• Quick Ratio: 1.57

Sales & Book Value

• Annual Sales: $2.64 billion
• Price / Sales: 0.71
• Cash Flow: $2.15 per share
• Price / Cash Flow: 9.77
• Book Value: $6.28 per share
• Price / Book: 3.34

Miscellaneous

• Outstanding Shares: 88,650,000
• Free Float: 88,516,000
• Market Cap: $1.86 billion
• Optionable: Optionable
• Beta: 1.14